Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Pfizer is likely to show GSK significant competition
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Farxiga is expected to have such a strong influence on the market due to the impressive results
The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
The partnership will capitalize on the combined capabilities of the two organizations
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Subscribe To Our Newsletter & Stay Updated
